AUCD: Concurrent Sessions: Group 4: Value Assessments and their potential for discrimination
Download |
PIPC AUCD Panel.pptx [download] |
Presenter
Sara van Geertruyden, BA, JD, Executive DirectorTEST Center
Description
Metrics for measuring ?cost effectiveness? or value of treatments often relies on discriminatory methods, like the quality-adjusted-life-year (QALY), which values the lives of people with disabilities as worth less than non-disabled people. Value assessment is increasingly at the center of state and federal discussions about drug pricing. This panel gives an overview of value assessments, their potential for discrimination, and related public policy threats at the federal and state level.Back to Session: Concurrent Sessions: Group 4